EGFR and non-small cell lung carcinoma: This bTMB assay was prospectively evaluated in the phase II, open-label, Blood First-Line Ready Screening Trial (B-F1RST) that evaluated the efficacy and safety of first line atezolizumab monotherapy in patients with EGFR/ALK wild type locally advanced or metastatic NSCLC, regardless of PD-L1 expression.